3 Funding Trends Happening in Washington State
Washington’s biotech market is far from frothy, but industry observers say there are a few trends to watch.
When Alpine Immune Sciences announced it had gotten $48 million from health care investment firms earlier this week, it was following a national trend of companies seeking strategic investors.
There is “more of a push for companies to look at strategic investors,” or those who can provide both money and business advice, said Life Science Washington’s Yesenia Green, who specializes in commercializing biotechnologies.
When Alpine Immune Sciences announced it had gotten $48 million from health care investment firms earlier this week, it was following a national trend of companies seeking strategic investors.
There is “more of a push for companies to look at strategic investors,” or those who can provide both money and business advice, said Life Science Washington’s Yesenia Green, who specializes in commercializing biotechnologies.